Shinsuke Shiotsu
About
Shinsuke Shiotsu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology.
According to data from OpenAlex, Shinsuke Shiotsu has authored 41 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Shinsuke Shiotsu's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Shinsuke Shiotsu is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Shinsuke Shiotsu collaborates with scholars based in Japan, United Kingdom and Greece. Shinsuke Shiotsu's co-authors include Koichi Takayama, Tadaaki Yamada, Takayuki Takeda, Yusuke Chihara, Junji Uchino, Yoshiko Kaneko, Noriya Hiraoka, Yuki Katayama, Akihiro Yoshimura and Osamu Hiranuma and has published in prestigious journals such as Scientific Reports, Medicine and The Oncologist.
In The Last Decade
Shinsuke Shiotsu
40 papers receiving 455 citations
Peers
Shinsuke Shiotsu
Joshua E. Reuss United States
Yosuke Kawashima Japan
Yan-Ping Mao China
Munehiro Ito Japan
Esmée P. Hoefsmit Netherlands
Jennifer L. Cultrera United States
Prakash Neupane United States
Filippo Venturini Italy
Kuninobu Kanai Japan
Susumu Hirosako Japan
Citations per year, relative to Shinsuke Shiotsu Shinsuke Shiotsu (= 1×)
peers
Joshua E. Reuss
Countries citing papers authored by Shinsuke Shiotsu
Since
Specialization
Citations
This map shows the geographic impact of Shinsuke Shiotsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinsuke Shiotsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinsuke Shiotsu more than expected).
Fields of papers citing papers by Shinsuke Shiotsu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shinsuke Shiotsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinsuke Shiotsu. The network helps show where Shinsuke Shiotsu may publish in the future.
Co-authorship network of co-authors of Shinsuke Shiotsu
This figure shows the co-authorship network connecting the top 25 collaborators of Shinsuke Shiotsu. A scholar is included among the top collaborators of Shinsuke Shiotsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinsuke Shiotsu. Shinsuke Shiotsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Katayama, Yuki, Tadaaki Yamada, Ryo Sawada, et al.. (2024). Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer. The Oncologist. 29(5). e681–e689.
2.
Onoi, Keisuke, Tadaaki Yamada, Kenji Morimoto, et al.. (2024). Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients. Targeted Oncology. 19(3). 411–421.
3.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2023). TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100494–100494.
4.
Morimoto, Kenji, Tadaaki Yamada, Ryo Sawada, et al.. (2023). Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology Immunotherapy. 72(6). 1699–1707.
5.
Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers. 15(5). 1543–1543.
6.
Tanimura, Keiko, Takayuki Takeda, Akihiro Yoshimura, et al.. (2023). Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers. 15(17). 4358–4358.
7.
Yamada, Tadaaki, Satomi Tanaka, Shinsuke Shiotsu, et al.. (2023). Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer. Cancer Medicine. 12(8). 9097–9105.
8.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study. Targeted Oncology. 18(5). 657–665.
9.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100493–100493.
10.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy. Drugs & Aging. 40(6). 563–571.
11.
Hirano, Keita, Takayuki Nakano, Nobuyo Tamiya, et al.. (2023). Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study. Thoracic Cancer. 14(11). 1004–1011.
12.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388.
13.
Fujii, Hiroyuki, et al.. (2021). Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Current Problems in Cancer. 45(6). 100739–100739.
14.
Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2021). Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics. 11(12). 2170–2170.
15.
Morimoto, Kenji, Tadaaki Yamada, Shinsuke Shiotsu, et al.. (2021). Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study. Thoracic Cancer. 13(2). 173–181.
16.
Tsuji, Taisuke, Yosuke Matsumoto, Shinsuke Shiotsu, et al.. (2020). A case of non–small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab. Current Problems in Cancer. 45(3). 100686–100686.
17.
Yamada, Tadaaki, Yuki Katayama, Akihiro Yoshimura, et al.. (2019). Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer. Cancer Medicine. 8(4). 1521–1529.
18.
Yoshimura, Akihiro, Tadaaki Yamada, Taisuke Tsuji, et al.. (2019). Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis. Thoracic Cancer. 10(3). 557–563.
19.
Yoshimura, Akihiro, Tadaaki Yamada, Takayuki Takeda, et al.. (2019). Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers. 11(3). 365–365.
20.
Katayama, Yuki, Takayuki Shimamoto, Tadaaki Yamada, et al.. (2019). Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 9(1). 102–102.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joshua E. Reuss Breakdown of academic impact, for papers by Yosuke Kawashima Breakdown of academic impact, for papers by Yan-Ping Mao Breakdown of academic impact, for papers by Munehiro Ito Breakdown of academic impact, for papers by Esmée P. Hoefsmit Breakdown of academic impact, for papers by Jennifer L. Cultrera Breakdown of academic impact, for papers by Prakash Neupane Breakdown of academic impact, for papers by Filippo Venturini Breakdown of academic impact, for papers by Kuninobu Kanai Breakdown of academic impact, for papers by Susumu Hirosako